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Summary of the Thesis 
Objectives: To evaluate the adherence to and the outcome of an evidence-based treatment 
algorithm for asthma in an emergency department (ED). Design: A non-randomized, 
controlled trial. Subjects were adults aged > 14 years with a diagnosis of acute asthma 
exacerbation. We compared treatment and outcome before (n= 330, 2000) and after 
(n=344, 2001) the introduction of a simple but evidence based treatment algorithm. The 
algorithm included: 1) a combination of nebulized salbutamol and ipratropium as first line 
treatment; 2) intravenous hydrocortisone and magnesium sulfate with repeat nebulizations 
as second line treatment and 3) oral prednisolone on admission to ED & upon discharge. 
Results: The use of oral prednisolone at ED admission increased from 42% to 65% 
(p<0.001), combination of salbutamol and ipratropium bromide in 1st line treatment 
increased from 55% to 94% (p<0.001), oral prednisolone on ED discharge increased from 
72% to 90 %( p<0.001), and an increase in intravenous hydrocortisone when admitted 
from 52% to 69% (p=0.009). The admission rates (38% Vs 35%) and mean of length of 
stay (LOS) in hospital (5.21 days Vs 4.49 days) were not significantly reduced. 
Conclusion: We found that introduction of a simple treatment algorithm in the ED resulted 
in  (1) a significantly improved compliance with evidence based treatment but (2) no 
significant reductions in admission rates or LOS. 
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Chapter 1 Background 
1.1 Current views on asthma 
1.1.1 Definition 
Asthma is not caused by a single factor, but by many cells and cellular elements playing a 
role in it, in particular, mast cells, eosinophils, T Lymphocytes, macrophages, neutrophils, 
and epithelial cells. As the mechanism of asthma has not been completely uncovered, the 
definition of this disease is not unified. Here, we introduce the one from the expert panel 
report 2, published by National Heart, Lung, and Blood Institute of the National Institutes 
of Health from the USA (EXPERT PANEL REPORT 2). Asthma is a chronic 
inflammatory disorder of the airways in which many cells and cellular elements play a 
role, in particular, mast cells, eosinophils, T lymphocytes, macrophages, neutrophils, and 
epithelial cells. In susceptible individuals, this inflammation causes recurrent episodes of 
wheezing, breathlessness, chest tightness, and coughing, particularly at night or in the 
early morning. These episodes are usually associated with widespread but variable airflow 
obstruction that is often reversible either spontaneously or with treatment. The 
inflammation also causes an associated increase in the existing bronchial hyper 
responsiveness to a variety of stimuli. 
1.1.2 Classification  
Asthma can be classified into two categories: atopic and non-atopic. The classification is 
based on whether specific IgE antibodies to environmental allergens are identified. 
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Asthma is a chronic relapsing and remitting disorder involving episodic reversible airway 
obstruction due to bronchospasms, increased mucus secretion and mucosal cell edema. 
This makes breathing more difficult and may result in respiratory failure. Asthma may 
occur due to an allergy (atopic/extrinsic) or because of other factors (non-atopic/intrinsic). 
Both causes are equally common. Asthma attacks vary in duration, intensity and 
frequency. Attacks may be mild to life threatening, occur suddenly or with premonitory 
symptoms, and may occur at any time, even in sleep. Symptoms of airway obstruction can 
persist between acute episodes. 
If allergic, the best treatment to control symptoms and decrease relapse, if possible, is 
prevention by elimination of the causative agent from the person's environment. 
1.1.3 Risk and trigger factors 
Although we may not know the real causative agents for many patients with asthma, many 
risk factors are found, which increase the probability of asthma development, 
increase tendency to asthma attacks by inducing airway inflammation and /or acute 
bronchoconstriction. Accordingly, patients are advised to avoid exposure to some factors, 
such as smoking, air pollution, aspirin, pollens and molds.  
Common triggers of asthma attacks include inhaled irritants, inhaled allergens, and viral 
infections of the respiratory tract. Most viral infections that could be associated with 
asthma attacks are difficult to document by commonly available means, so the diagnosis is 
often presumptive, made on the basis of history and physical examination findings.  
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Airway inflammation may be induced by viruses, which produce a variety of 
inflammatory mediators both directly and indirectly. The mediators cause 
bronchoconstriction and airway edema.  
1.1.4 Further understanding of the pathogenesis  
As mentioned before, asthma is not a single disease entity but rather a syndrome with a 
multitude of presentations and, most likely, a multitude of causes. Traditionally, asthma 
has been regarded as a manifestation of an underlying abnormality of airway smooth 
muscle and its neural control systems. However, more recent and current evidence 
suggests that in many patients, asthma is an inflammatory disease of the airways. 
Pathologic evidence shows that many inflammatory cells and mediators take part in it, for 
example, eosinophils, lymphocytes, mast cells (Rowe, 2001). Each cell has an important 
contribution and a specific relation to the development of airway inflammation.  
Consequently, these cells have become an important target of treatment in the clinical 
management of asthma. Understanding how these cells participate in allergic 
inflammatory events and how their function can be regulated by therapeutics has provided 
insights into asthma pathogenesis and mechanisms of drug action. 
1.1.5 Emphasis on anti-inflammation in asthma treatment 
Since the definition of inflammation has been proven by biopsies, treatment by anti-
inflammatory drug has been emphasized recently. Studies have shown that improvement 
in asthma control achieved by inhaled corticosteroids is associated with improvement in 
markers of airway inflammation. These observations indicate that a strong link may exist 
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between features of airway inflammation, bronchial hyper responsiveness, and asthma 
symptoms and severity. Corticosteroids affect inflammatory cells through several 
mechanisms described below: corticosteroids decrease airway mast cell numbers, and 
through this diminish the immediate response to antigen (Barnes,1992); corticosteroids 
induce eosinophil apoptosis and in this way it can not release inflammatory mediators 
(Goldie,1995); corticosteroids decrease expression and generation of proinflammatory 
cytokines (Horwitz,1995), which are generated principally by the T-lymphocyte.   
1.2 Summary of guidelines 
1.2.1 Guidelines arise in need 
In recent decades there have been striking advances in the clinical treatment of asthma, but 
morbidity and mortality for the disease are still high. That is due mainly to under-
detection of disease severity and inappropriate therapy. The National Asthma Education 
and Prevention Program (NAEPP) comprised of the National Heart, Lung, and Blood 
Institute (NHLBI) of the National Institutes of Health (NIH) in the USA initially 
published guidelines for the diagnosis and management of asthma in 1991.The guidelines 
were based on expert opinion and experience. The purpose of the guidelines was to 
provide assistance to clinicians in the diagnosis and treatment of asthma when they 
encounter different conditions, to help public health officials, and program planners take 
action to control asthma and reduce its personal, social, and economic burdens. 
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1.2.2 Concept of containment at Emergency Departments 
Meanwhile, management for acute exacerbation at Emergency Departments (ED) is a 
crucial opportunity to minimize these burdens. Because with appropriate treatment at ED, 
there are three ways to decrease cost: 1) first it can lessen cost at ED, only using drugs in 
need, no more unnecessary ones (Suh, 2001); 2) with appropriate methods of assessment 
and intensive use of therapy, excess hospitalization can be avoided (Suh, 2001; Akerman, 
1999); 3) giving patients a good action plan and follow-up schedule can decrease asthma 
relapse and repeat attendance to ED (Bolton, 1991; ED Manag, 2001);  
1.2.3 Guidelines in USA 
With understanding of the importance of management in the emergency room, numerous 
clinical guidelines on acute exacerbation of asthma have been disseminated. In November 
1997, the National Asthma Education and Prevention Program (NAEPP) released the final 
version of its comprehensive second Expert Panel Report. This is revision of the one 
published in 1991. In 1995 the NAEPP convened a second expert panel to update the 
guidelines to reflect important scientific and clinical advances, through critical review of 
evidence based literature.  
The panel’s recommendations for acute asthma care stressed the use of aggressive inhaled 
ß2-agonist therapy, early systemic corticosteroid administration, anticholinergics as add-
on drugs to ß2-agonist in those with severe attack, and oral systemic corticosteroids for 3 
to 10 days after discharge (Wiliam, 1998).  
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1.2.4 Guidelines in Canada 
In Canada, guidelines for the emergency management of asthma were set up by members 
of the Canadian Association of Emergency Physicians (CAEP) and the Canadian Thoracic 
Society (Guidelines for Canadian Clinical Practice Guidelines). Recommendations are 
similar to the ones in the United States:  Beta2-agonists are the first-line therapy for the 
management of acute asthma in the emergency department; anticholinergic therapy should 
be added to ß2-agonist in severe and life-threatening cases and may be considered in cases 
of mild to moderate asthma; all patients should be considered candidates for systemic 
corticosteroid therapy at discharge. The different point in the Canadian guidelines is that 
adrenaline is recommended as an alternative to conventional therapy in unresponsive life-
threatening cases (Evans, 1993).  
1.2.5 Common features in guidelines 
There are other guidelines generated by some organizations, such as British asthma 
guidelines coordinating committee, Thoracic Society of Australia and New Zealand, and 
the Singapore Ministry of Health in 2002. Though some specific steps are different among 
these guidelines, the outline of the main points is the same, containing four sections: 
Measures of assessment and monitoring, Control of factors contributing to asthma 
severity, Pharmacologic therapy, and Education for a partnership in asthma care.   
Making the correct diagnosis of asthma is extremely important. Clinical judgment is 
required because signs and symptoms vary widely from patient to patient as well as within 
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each patient over time. During therapy, periodic assessment is also required, to establish 
whether the goals of asthma therapy have been achieved.  
Exposure of sensitive patients to inhalant allergens has been shown to increase airway 
inflammation, airway hyper responsiveness, asthma symptoms, need for medication, and 
death due to asthma (Vervloet 1991; Kuehr, 1995; Leung, 2002). Substantially reducing 
exposures significantly reduces these outcomes.  
Observations into the basic mechanisms of asthma have had a tremendous influence on 
therapy. Because inflammation is considered an early and persistent component of asthma, 
therapy for persistent asthma must be directed toward long-term suppression of the 
inflammation. Inhaled corticosteroids are the preferred first-hand medication for 
suppression of asthmatic inflammation. 
Education remains the cornerstone of asthma management and should be carried out by 
health care providers delivering asthma care. Education should start at the time of asthma 
diagnosis and should be integrated into every step of clinical asthma care. Asthma self-
management education should be tailored to the needs of each patient, maintaining 
sensitivity to cultural beliefs and practices.  
2.2.6 Evaluation of clinical practice guidelines 
Although many asthma practical guidelines have been published in the past decade, the 
morbidity and mortality for the disease are still high. In 1995, there were an estimated 1.9 
million ED visits for asthma in the United States. Hence, some programs were carried out 
to help bridge the gap between practice guidelines and the reality of current asthma 
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management. Despite advances in drug treatment, outcomes of patients with asthma 
remain largely unsatisfactory. Low rates of patient compliance to the prescribed treatment 
regimen, inadequate physician-patient communication, and inconsistent implementation of 
evidence-based treatment guidelines are the most important causes for the poor outcomes. 
Physician and patient adherence to the guidelines is an important factor in the control of 
asthma. Recently in several articles, researchers have suggested that the under utilization 
of the asthma guidelines may in part be related to a lack of understanding (Courtney, 
2000; Wan, 2002). 
1.3 Use of guidelines in routine practice 
1.3.1 Chicago-area survey 
A cross-sectional, self-administered survey of ED asthma care was conducted in 1996 to 
1997. Sixty-four EDs took part in the study, with a response rate of 71.9%. Systemic 
steroids (either IV or po) were estimated to be given to 73.2 ± 3.9% of patients during their 
ED visits. Systemic steroids were prescribed for 55.9 ± 3.5% of patients at time of 
discharge. Only 57.0 ± 5.4% of patients were estimated to have received any type of 
written asthma educational material (Michael, 1999).  
The medical directors reported that many of the Chicago-area EDs provided asthma care 
that was consistent with key aspects of national guidelines. However, in certain critical 
areas of care, the EDs demonstrated a high degree of variation. In view of this, we are 
unable to declare that guideline compliance was poor in the Chicago area, because this 
study has several limitations. First, the study was based on self-reported perceptions of the 
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medical directors of the EDs. Some physicians liked the way questionnaire was asked, 
while others did not, therefore certain bias might have existed between respondents and 
non-respondents; Secondly, the responses were not verified by direct observation or chart 
audit, so accuracy of recall was doubtful. 
1.3.2 Canadian survey 
From July 1, 1997 to November 18, 1997 a retrospective chart collection and review was 
conducted in Canada, to compare the results with accepted management guidelines for the 
emergency department treatment of asthma. In contrast to management guidelines, only 
59% of patients received treatment in the emergency departments with inhaled or systemic 
corticosteroids. Furthermore, specific follow-up plans were infrequently documented in 
the emergency department charts (37%) (Reid, 2000). Adherence with published Canadian 
guidelines for the emergency department management of acute asthma exacerbations was 
suboptimal. Corticosteroid use in the emergency department was significantly less than 
recommended. 
1.3.4 Hypothesis on poor compliance 
Why does poor compliance with guidelines exist universally for so many years after their 
introduction? Some surveys show that the reason is partly due to a lack of understanding 
of the guidelines. There are too many guidelines, and each one seems as huge as a book. 
Working in busy EDs, it is difficultfor medical staff to devote toomuch time to read 
lengthy guidelines. So we feel that, simple treatment steps may be easier to teach, learn 
and practice.  
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Asthma management evolves with the advance in knowledge of its pathogenesis, and 
significant progress has been made. But an update of guidelines takes several years, and 
the dissemination after a new version has been published also takes more time. 
(Guidelines were issued by the expert panel’s review of the literature, experience and 
opinion). Compliance with guidelines is not adequate in many aspects. 
1.3.5 Asthma surveillance in Singapore 
Ng et al have conducted a series of studies on adult asthma in Singapore that describe the 
prevalence, morbidity and mortality and their relationships with environmental and 
medical care factors. These studies showed that there was no evidence of a temporal 
increase of mortality from 1976 to 1995 for adults and there is considerable morbidity 
among asthmatics, corticosteroids are under-used, and patients' knowledge and self-
management skills are poor (Ng,1999; Tan, 2000). 
The latest survey on asthma in the primary care was conducted in late 2001. A group of 
family physicians were investigated with regards to  their asthma management using a 
self-administered questionnaire. There was much disparity between the recommendations 
by international guidelines on asthma management and current practice in reality. This 
was attributed to both patient's and doctor's factors (Tan, 2001). From previous studies, we 
can find that similar problems do exist in Singapore, like inappropriate asthma 
management and variation in compliance with guidelines.  
To reduce the inappropriate management of asthma, the Singapore Ministry of Health 
(MOH) published clinical practice guidelines----management of asthma in January, 2002, 
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to work towards the goal of reducing asthma morbidity and mortality (MOH Clinical 
Practice Guidelines 1/2002). 
1.4 Specific aims 
1.4.1 Asthma mortality and morbidity trends 
Asthma is a common chronic inflammatory disease, which affects quality of life in 
patients and even threatens many people’s lives. Despite more understanding in the 
pathobiology of asthma and advancement in drug therapy over recent years, most well-
conducted studies suggest that the prevalence of asthma has been increasing in children 
and young adults for the last several decades by approximately 5% to 6% per year 
worldwide. In the United States, asthma affected between 9 and 12 million persons in 
1987, 14 million to 15 million persons in 1995 (Evans,1987). Asthmatics have 470,000 
hospitalizations annually. More than 5,000 people die of asthma annually. In Singapore, it 
is estimated that 140,000 individuals have current asthma and more than 100 individuals 
die of this disease annually (Chew, 1999). 
1.4.2 Economic burden 
These increases have laid the economic burden to the whole society. The cost of illness 
related to asthma in 1990 in the United States was estimated to be $6.2 billion. Inpatient 
hospital services represented the largest single direct medical expenditure for this chronic 
condition, approaching $1.6 billion. Forty-three percentage of its economic impact was 
associated with emergency room use, hospitalization, and death. (Weiss, 1992) In Canada, 
the total cost of asthma was estimated to be between $504 million and $648 million. The 
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single largest component of direct costs was the cost of drugs ($124 million) (Krahn, 
1996). Acute asthma (emergency department visits and hospitalization) accounted for 
approximately 25% of the total cost associated with asthma care (Bloch, 1995). In 
Singapore, the total cost of asthma was estimated to be US$33.93 million per annum. 
Inpatient hospitalization accounted for the largest proportion of direct medical expenditure, 
approximately US$8.55 million (Chew, 1999). 
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Chapter 2 Methodology 
2.1 Study setting and design 
In 2001, we conducted a Hospital-based retrospective chart review with the ED electronic 
records and medical treatment cards of all adult patients who had an ED ID code of 
asthma (493.9).  
The objective of this study was to evaluate the adherence to and efficacy of a management 
algorithm for acute asthma in the ED, with focus on evidence-based treatment steps rather 
than documentation and patient classification.  
The study was performed at National University Hospital, Singapore, a large community-
based teaching hospital that provides tedious health care. Research targets were patients 
who were admitted to ED with a diagnosis of asthma. 
This is a retrospectively controlled study of all adult patients admitted for the treatment of 
acute asthma in the same ED over two epochs (February to May inclusive) in consecutive 
years 2000 and 2001. We compared the treatment intensity and clinical outcomes of 
patients managed in the usual manner before our intervention and following the 
intervention program which was instituted in January 2001.  
2.2 Description of intervention program 
An evidence-based clinical algorithm which was easily understood and acceptable to 
doctors was developed. Both emergency and respiratory medicine specialists critically 
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reviewed a total of 169 articles, out of which 8 were Meta analyses on efficacy of 
corticosteroids, ipratropium bromide, magnesium sulfate and aminophylline in acute 
asthma. These articles were searched out in the literature for clinical evidence on the 
management of acute asthma by using MEDLINE (PUBMED) and COCHRANE 
electronic databases using the key words “acute asthma” and “randomized” and/or “meta 
analysis” dated to December 2000. Recommendations were introduced after review of the 
clinical evidence in the local context, with the following features:  
1. Simple treatment algorithm rather than a complex clinical pathway 
2. Emphasizing evidence-based treatment steps rather than precisely documenting 
disease severity and pulmonary function. Based on a study which aimed to assess the 
efficacy of a PEFR guided protocol in treating ED asthma. Data showed that in the 
management of acute asthma in the ED, a PEFR guided protocol neither improved 
overall PEFR response to treatment nor reduced admission rates when compared with 
current management as it is practiced in Singapore (Abisheganaden, 1998).  
3. Enhancing second-line therapy to avoid inappropriate hospital admissions, patient 
disposition based upon symptoms and physical signs rather than pulmonary function 
testing, and 
4. Initiating short and long-term preventive care at the ED. Short term aims to gain 
prompt control of inadequately controlled persistent asthma or severe acute 
exacerbations. Long term aims to reduce frequency and severity of asthma 
exacerbations. 
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2.3 Evidence for specific  recommendations 
2.3.1 Corticosteroid and ipratropium bromide in first line treatment 
The recommendations are based on clinical evidence of a high quality. Corticosteroids are 
the most effective drugs in the treatment of asthma. They cause marked improvement in 
airway inflammation and lung function. Early use of corticosteroids at an ED significantly 
reduced the need for hospital admission in patients with acute asthma, and a short course 
of corticosteroids for follow-up significantly reduces the number of relapses to additional 
care (Rowe, 2002; Plotnick, 1998). Ipratropium bromide may relieve cholinergic 
bronchomotor tone and decrease mucosal edema and secretions (Aaron, 2001). The 
addition of ipratropium to beta2-agonists improves lung function and decreases 
hospitalizations without risk of adverse effects (Stoodley, 1999). 
2.3.2 Magnesium sulfate  and adrenaline in second line treatment 
We noted that not all treatment options in the algorithm are strictly evidence-based. For 
example, there was no conclusive evidence for magnesium or adrenaline as second or 
third-line drugs in status asthmatics. They were included in the algorithm because we felt 
that, despite the lack of agreement on their application, a rapidly escalating intensity in 
bronchodilator treatment and thus a broad range of treatment options should be executed. 
Some studies already have been conducted to determine whether magnesium sulfate 
(MgSO4) has a clinical effect in asthma and results have been conflicting, either in 
positive or in negative way. In Gustavo Rodrigo’s study, a meta-analysis of randomized 
trials, pooled results revealed that MgSo4 did not decrease significantly admission rates 
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(Rodrigo, 2000); therefore, the addition of MgSo4 to ED patients with moderate to severe 
asthmatic exacerbations does not alter treatment outcomes. Nevertheless, the number and 
size of studies being pooled remains small, so further definitive controlled studies are 
needed to clarify its efficacy.  
In research to demonstrate the impact of MgSo4 on expiratory flow in acute asthma 
exacerbations, Brian et al concluded that use of IV magnesium sulfate in addition to 
standard therapy does not provide clinically meaningful improvement of objective 
measures of expiratory flow in patients with moderate to severe asthma (Tiffany, 1993). 
But there is also evidence showing that intravenous MgSo4 decreased admission rate and 
improved FEV1 in patients with acute severe asthma (Bloch,1995) and it appears to be 
safe (Rowe,2000). A cellular mechanism for this bronchodilation effect has been proposed 
that it may involve smooth muscle relaxation via calcium antagonism (McLean, 1994). 
Mgso4 may also have a beneficial anti-inflammatory effect through affecting 
polymorphonuclear neutrophils by interfering with extracellular Ca2+ influx (Cairns, 
1996).  
Adrenaline is recommended as an alternative to conventional therapy in unresponsive life-
threatening cases in Canada (Beveridge, 1996).  
2.3.3 The key interventions in the asthma clinical algorithm 
1) A combination of nebulized salbutamol and ipratropium as first line treatment;  
2) Intravenous hydrocortisone and magnesium sulfate with repeat nebulizations in second 
line treatment  
3) Early administration of a systemic corticosteroid 
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4) A course of oral prednisolone for all patients discharged from the ED 
5) Fast track referral to a specialist clinic for all patients discharged from the ED 
The management of Adult Acute Asthma is based on clinical evidence, as shown in the 
following flow chart (Thomas, 1995; Brenner, 1983; McFadden, 1989; Rodrigo, 1993). 
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Sym ptom s 
of life-threaten ing 
asthm a present?
• S ilent chest
• Cyanosis
• Feeble resp iratory effort
• Exhaustion, confusion or obtundation
• PEFR<35%  of predicted
YES (present)
Drug T herapy
1. Salbutam ol (ventolin) nebulised therapy: 1m l (5m g) salbutam ol w ith 2m ls (0.5 m g) ipratrop ium  
brom ide & 2m ls N/S to m ake up to 5m ls. R epeat  tw ice
2. Oral prednisolone 0.5 - 1m g/kg (m ax 60m g)
NO 
(not present)
Sup portive M easures
1. Managed in P1 area w ith supplem ental O2, h igh flow . 
2. Monitoring: ECG, pu lse oxim etry, vital signs q5-10m ins.
3. IV  access 500m ls crystalloid  over 3-4 hours
4. Prepared for rapid  sequence intubation: have paralysing and sedating drugs read ily availab le.
5. Use serial ABG’s to detect triad of progressive hypoxaem ia , hypercapnia and acidosis.
6. Ind ications for intubation: persistent hypercarb ia, severe hypoxia w ith PaO2 <60.
7. CXR: patients not resp onding to in itial therapy.
Non-respo nd ers/partia l respons e
1. PEFR <50%  pred icted w ith in 60m ins: 
repeat neb 2 - 3 tim es utilising
salbutam ol 5m g or 7.5m g w ith 0.5m g 
ipratropium , 1.5m ls N/S to 5m ls.
2. Corticosteroids: H ydrcortisone 400 -
500m g I/V .
3. I/V  Mg SO4 1 - 2gm slow  bolus (20 
m ins)
4. Adrenaline: (use w ith caution if at all 
in  elderly, IHD or severe hypertension) 
0.3 - 0.5m ls 1 :1000 solutions S/C q 20 
m ins;
OR Terbutaline: (m ore β2 selective than 
adrenaline) 0.25m ls S/C 20-30 m ins
prn.
Consid er ad m iss ion
1. Patient unab le to attain PEFR 
≥50%  desp ite therapy and 
observa tion 1 - 2 hours.
2. Previous intubation / ICU 
adm ission
3. Xray evidence of 
pneum othorax
or pneum onia
Im pro vem ent
All other asthm atics/COLD patients
1. Check patient and PEFR: (optional 
and m ust also m easure height) 
baseline and after 2 neb doses.
2. Reassessm ent: if PEFR ≥50%  and 
subjective im provem ent consider 
d ischarge w ith early follow  up 
w ith in 48 hours (Respiratory 
Medicine C lin ic).
3. A ll patients at d ischarge should  
receive oral prednisolone 0.5 -
1m g/kg/day (40m g m ax no tail) 
for 7 - 10 days and follow  up.  
4. Add itional: inhaled steroids 
(pu lm icort turbohaler 200m cg bd).
ASTHM A CLINICAL ALGORITHM
Re-Evaluate
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The algorithm was disseminated to residents, fellows and consultants (total of 25 doctors) 
in January 2001 and the protocol, treatment steps and disposition of patients were briefly 
introduced. 
2.4 Selection of patients 
All adult patients (age>14 years) with a discharged ICD code for asthma (493.9) admitted 
through the ED were included. Following individual chart review, patients who had 
diagnosis of chronic obstructive pulmonary disease, cardiac asthma, tumor, bronchiectasis, 
acute bronchitis or pneumonia were excluded. Patients in whom the clinical diagnosis of 
asthma was not made with confidence were also excluded. Clinical severity was 
categorized according to simple rules developed in the ED for triage and initial disposition. 
(See Table 5, it will be clarified later) 
2.5 Data collection procedures 
Data collection came from three sources: (1) Original paper-based data lodged at the 
Medical Record Office, (2) e-database at ED reservoir; information on in-patient at 
National University Hospital and, (3) In-hospital demographics and process measures 
were assessed by clinical chart review. Data collected included age, gender, ethnicity, 
hospital admission and discharge PEFR, pulse oximetry measurements, and arterial blood 
gases. In addition, length of stay (LOS), and possible antibiotic use were documented.  
Cases were classified into two groups: patients admitted between February to May 2000, 
before introduction of the clinical algorithm; patients admitted during the same month in 
2001, after dissemination of the clinical algorithm. 
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In the process of data collation, we used the paper-based as the primary data source. The 
paper records were the default in cases of in consistencies.  In the vast majority of cases 
(over 95%) the hard copy records were used, in the rare case where case notes were not 
available we used the e-data source. 
2.6 Statistical methods 
Data was analyzed using SPSS software. The results were expressed and comparisons 
between the two study groups were made on the basis of acute asthma episodes rather than 
as individual patients. All values were expressed as mean + SE and, where appropriate, 
95%confidence interval. Comparison between the two groups was made using Student’s 
unpaired t-test for parametric data and χ 2 tests for non-parametric data. P values of <0.05 
were considered statistically significant.  
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Chapter 3 Results 
3.1 Description of study patients 
After reviewing the data from Icare (e-database at NUH), we found that, in 59 episodes,' 
the final diagnosis were not asthma. Examples of eventual diagnoses are “chronic airway 
obstruction, pneumonia, situs inversus, senile cataract, lumbago, congenital anomalies of 
spine" etc. This might have resulted from revision in the final diagnosis of patients who 
were wrongly diagnosed in the ED as having asthma. There episodes were excluded from 
our analysis. 
From February to May 2000, a total of 364 episodes of adult asthmatics were identified 
from the ED register. Thirty-four were excluded from analysis: 18 had an uncertain 
diagnosis. Of the remaining eligible asthmatic episodes, 9 had no medications documented 
and 7 were missing records, therefore, a total of 330 episodes were included in the 
analysis (91%). 
From February to May 2001, a total of 388 episodes of adult asthmatics were identified 
from the ED register. Twenty-one were excluded from analysis: 9 episodes which were 
not asthmatics and 12 which had an uncertain diagnosis. Of the remaining 367 eligible 
asthmatic episodes, 23 were excluded due to incomplete or missing data, leaving 344 
asthmatic episodes for analysis (89%). 
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3.2 Tables and figures  
There were a total of 330 episodes in 2000 and 344 episodes in 2001. Patient 
characteristics on ED admission are depicted for both groups in Table 1. These two groups 
were similar with respect to patient demographics. Severity of disease was defined by 
symptoms and physical signs, categorized according to simple rules developed in the ED 
for triage (Table 6). As noted in Table 5, significantly more patients in triage P1 in 2000 
than in 2001 and respiratory rate much quicker in 2000 as well.  
Table 1 Characteristics of  patients  
(+SE) Year 2000 Year 2001  
Total number of  episodes 364 388  
Number studied 330 (91%) 344 (89%)  
M/F ratio 0.49 0.51 ns 
Age (yrs) 43 (1) 44 (1) ns 
Chinese 44% 41% ns 
The average dose of medication for oral prednisolone and IV hydrocortisone in 2001 is 
significantly higher than in 2000 (Table 2).  
Table 2 Corticosteroid dose 
 (+SE) YEAR 2000 YEAR 2001 P 
ORAL PRED (mg) 32(0.8) 43(0.8) <0.001 
Intra-venous  hydrocortisone (mg) 195(3) 348(9) <0.001 
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From Table 3, among patients who were admitted to the ward, there was a significantly 
higher dosage in 2001 than in 2000, in the medication of oral prednisolone, IV 
hydrocortisone, and atrovent. But length of stay at ward and expenditure at ward were not 
significantly decreased. 
Table 3 Outcome & treatment when patients were admitted 
 (+SE) Year 2000 Year 2001 p 
Oral pred (mg) 33.51(1.2) 42.16(2.0) 0.001 
IVhydrocort (mg) 196.0(4.0) 341.27(12.9) <0.0001 
Atrovent (ml)1ml/5mg 2.61(0.2) 5.6(0.2) <0.0001 
Length of stay (days) 4.79(0.7) 3.55(0.3) 0.11 
Cost (s$) 1889.58 1562.21 0.3 
Table 4 shows more intensive and aggressive treatment at ED in 2001 than in 2000. The 
total nebs used and dose of corticosteroids are much higher, and the P value is significant 
at less than 0.0001. 
Table 4 Comparison of asthma treatment in 2000 versus 2001 
 (+SE) Year 2000 Year 2001 P 
Total neb (times) 1.97(0.07) 2.33(0.05) <0.0001 
Oral pred (mg) 32.17(0.8) 42.98(0.8) <0.0001 
IVhydrocort (mg) 195.0(3.0) 348.54(9.3) <0.0001 
Figure 1 summarizes the compliance with and outcome of the clinical algorithm. The use 
of oral prednisolone at ED admission & on discharge, combination of salbutamol and 
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ipratropium bromide as 1st line treatment, and intravenous hydrocortisone when admitted 
increased significantly in 2001 compared with 2000. However, the admission rate was 
reduced but not significantly. 
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Chapter 4 Discussion 
4.1 Summary of findings 
There were three major findings in this study. First, following basic instructions on a set 
of simple recommendations for asthma treatment in the ED, the compliance with the 
algorithm in 2001, hadimproved significantly compared to that in 2000. Secondly 
however, the admission rate was not significantly decreased, with 38% in 2000 vs. 35% in 
2001. Third, the length of stay (LOS) showed little difference between these two groups.  
4.2 Comparison with previous studies 
Following the implementation of the algorithm, the compliance of nebulized salbutamol & 
ipratropium was 94%, oral prednisolone on EMD discharge 90%, oral prednisolone on 
EMD admission 65%, and IV hydrocortisone before ward admission 69% respectively. 
These outcomes are much higher than the ones in a similar study conducted in France.  
A 12-month cross-sectional observational cohort study in adult patients with acute asthma 
was carried out in France. The doctors used a formatted chart to describe information on 
asthma management. Initial treatment included nebulised ß2 agonists, anticholinergics, 
and systemic corticosteroids in 93%, 49% and 60%, respectively. The overall admission 
rate was 54.2% (Salmeron, 2001). In the report, Sergio et al mentioned that the high 
admission rate was mainly due to absence of standardized admission criteria. In our study, 
we encountered a similar problem (chapter 4.4).  
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4.3 Length of stay in the wards 
After excluding these patients who had inconsistent chart data, the average LOS was 4.79 
days in 2000; average LOS was 3.55 days in 2001. Although LOS decreased, this was not 
statistically significant. The lower length of stay in 2001 might be explained by more 
intensive and aggressive treatment at the EMD. Among patients who were admitted to the 
ward, significantly higher dosage of medication was administered in 2001 than in 2000, in 
the use of oral prednisolone, IV hydrocortisone, and atrovent (Table 3). But there was no 
decrease in cost. With increase in drug used at EMD and decrease in LOS at ward, it did 
not lead to overall reduction of economic burden.  So the question of how cost –effective 
more intensive asthma treatment in the ED really is needs to be resolved in further 
prospective studies. 
Table 5 Clinical severity 
(+SE) Year 2000 Year 2001 P 
SpO2 % 95 (0.002) 95 (0.002) 0.49 
Pulse R/m 105 (1) 102 (1) 0.068 
Resp R/m 23 (0.3) 22 (0.2) 0.005 
Triage class P1     
(see Table 6) 
11% 6% 0.02 
4.4 Weaknesses of the study 
The limitations in this study may be categorized into patient factors, treatment factors and 
other confounding factors. Firstly, the patients were not prospectively randomized but 
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were only historically controlled in terms of their enrollment during February to May of 
two consecutive years. Also the sample is not a big one, and it was selected by four 
continual months definitively and not randomized, so the two groups of patients may not 
have been comparable. Indeed, as we can see from Table 5, respiratory rate of patients in 
2000 is faster than the ones in 2001, and more patients in 2000 classified as triage P1. 
Since data collection is retrospective, some records were missing. However close to 90% 
of consecutive patients were included in the final analysis. Nevertheless, the patients in 
2001, despite having less severe asthma than patients in 2000, actually received more 
intensive asthma treatment in the ED (Table 4). This is further confirmation that our 
simple treatment plan facilitated a high degree of compliance in 2001. 
Secondly, the treatment during both study periods was not rigorously linked to a formal 
classification of asthma severity. Rather the emergency department in NUH classifies 
patients by a simple set of triage rules (Table 6). P1 marked as most severe asthmatics, 
and P3 as mild asthma attack. The treatment dose of an intensity was left to the judgment 
of the attending doctors in 2000 and guided by a simple treatment protocol in 2001(page 
18). This resulted in some variation in treatment intensity but it is clear that patients in 
2001 received more intensive and appropriate asthma treatment despite having overall less 
severe asthma than 2000.  
The usual practice is for  P1 patients to be  admitted to the resuscitation ward, and P3 
patients to routine waiting areas. Some of P2 were admitted, and part of P2 discharge, 
according to their response to therapy. But in this study, 7 patients categorized as P1 were 
also discharged. Thus, this triage classification system is also obviously not a reliable 
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predictor of the final decision on whether to admit or discharge patients after asthma 
treatment.  
Table 6 Triage classification in ED 
Priority 1 (P1) 
 
Signs of life threatening asthma usually brought in by ambulance 
directly to the resuscitation area 
Priority 2 (P2) Walked in but presenting with active signs of asthma e.g. audible 
wheeze 
Priority 3 (P3) All other patients not in P1 or P2 categories 
Traditionally, overall asthma severity has been defined by some combination of the 
following four features: symptoms, medication requirements, physiologic abnormalities, 
and morbidity. It is evident that most of these criteria (symptoms, beta2-agonist 
requirements, morbidity, and reduced flow rates) describe a lack of asthma control. 
Asthma severity and asthma control should be distinguished. Asthma severity should be 
defined by the minimum medication required to achieve adequate control rather than by 
symptoms and abnormal lung function (Cockcroft, 1996). A study was carried out to 
develop a simple and pragmatic procedure for applying the international consensus 
guidelines, to classify severity using information about symptoms, pulmonary function 
and asthma medication (Liard, 2000). 
Thirdly, the outcomes of this study were confounded by a lack of pre- defined criteria for 
evaluation of the response to treatment during that acute period and for the eventual 
disposition of patients.  One important outcome in evaluating the efficacy of a treatment 
algorithm for acute asthma is the hospitalization rate. However, the algorithm in this study 
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did not define the specific criteria for hospital admission but instead left it to the doctors in 
charge to decide subjectively. This may be the reason why there was no significant 
decrease in hospitalization rate in 2001 compared with 2000 despite less severe asthma 
and more intensive treatment regimens in the second year of the study. Because hospital 
admission was a clinical decision, it could have been biased by perceptions of either 
patients or doctors. However, the results of this study are an accurate reflection of the 
situation in current practice in the vast majority of EDs in the world where decisions on 
the patients’ response to treatment and eventual disposition are based upon subjective 
decisions and not formal protocols.  Further studies are needed on the impact of similar 
evidence based treatment plans with clear, prospectively defined objective criteria for 
hospital admissions.  
Brenner et al suggest that several points should be taken into consideration as to whether 
to discharge patients, to continue treatment, or to admit to hospital: the duration of the 
bronchospasm, frequency of visits, history of previous endotracheal intubation, pulse rate, 
accessory muscle use, range of peak expiratory flow rate, pneumonia, lability, prominent 
psychiatric difficulties, poor access to medications, poor educability, fear of steroids, 
patients on glucocorticoids or those who have recently stopped glucocorticoids, and 
evening discharges of patients from the ED, of which all predispose to relapses of acute 
asthma. (Brenner, 1998) Medical doctors might be surprised to know that they should 
screen for so many items before making a decision, to discharge patients or to admit them 
and may be less likely to comply with such a complex method of evaluation. 
However, this study was not designed to examine the impact of a treatment plan on 
hospital admission. Rather its main aim was to show the effect of a simple treatment plan 
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on compliance with evidence based management of acute severe asthma. In this regard, 
we have shown that following intervention, a significantly larger proportion of patients 
received the appropriate treatment steps even though overall they had less severe asthma 
than the control group of patients.  
4.5 Secondary results and their implications 
Though our main objective in this study was to compare the outcome and compliance of a 
clinical algorithm set at ED, between two groups before and after the introduction of this 
algorithm, when we combined these two groups as a whole, we found that:  
Overall, 674 episodes were analyzed. Of these, gender ratio is equally distributed, with 
female (49%) and male (51%). But in comparison to hospitalization, female (42.6%) is 
statistically higher than male (30.6%) (p=0.001) (Figure 2). 
In Trawick DR’s retrospective study, they compared the relative numbers and hospital 
course of men verses women admitted at least twice with asthma or status asthmatics to 
Yale-New Haven Hospital (YNHH) during the period from 1985 to 1994, and found that 
68.6% of the admissions were women. After chart review, they point out that the 
mechanisms contributing to the gender differences in asthma admissions may include 
differences in the ventilatory response to hypercapnea or in the tolerance to airway 
obstruction.  
From the figure below we can see that our results are very similar to Trawick’s with 
regards to in gender differences in the admission rate. And in this study, we do find that 
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some other differences in treatment between women and men, like average dose of oral 
prednisolone used at ED is higher in men (39.79mg) than in women (37.90mg). 










Agegroup1 Agegroup2 Female Male
Discharged Admitted
 
The mean age of targets is 43 years old. Two age groups are set with 43 as cut-off point, 
group1 (age<43) and group2 (age>43), Therefore no age bias between them, with 51% 
and 49% respectively. The admission rate is 28% versus 45% in two groups (P<0.001). 
The observation that older patients have higher admission rates is consistent with another 
local study (Lee, 2000).  
Table 7 shows the relationship between patient categorization according to triage rules in 
the EMD, admission rates and investigations.  
 
 
   32
Table 7 Triage classification, investigations and admission rate 
Triage classification  
(%) 




Arterial blood gas 
(%)
P1                      8.3  89.3 83.9 39.3
P2                     86.2 33.4 40.3 3.4
P3                       5.5 5.4 35.1 0
With regards to investigations, chest radiograph appear to have been over-used while 
arterial blood gas measurements were under-used. All practice guidelines recommend 
objective measurement of asthma severity, but there have been few prospectively 
controlled studies to show how best to use this information to guide treatment. 
Finally, I should point out that quite a few patients visited the emergency department 
several times within the four months of this study. In total there were 140 repeat cases 
among 674 (21%). Before introduction of this algorithm the number was 19%, and after 
the practice, it was 22%. This number is very high, and maybe it is in part the reason for 
the heavy economic burden. In Table 8, evidence showed that there were no obvious 
changes in ED repeat visits and relapse rates, despite the significant increasing use of oral 
prednisolone on discharge and more intensive therapy in ED, which were recommended in 
the clinical pathway. Some research on factors associated with repeat Emergency 
Department visits show that those not in possessions of a written asthma action plan were 
more likely to present frequently at the emergency department than those with such plans. 
(Adams, 2000) So we might consider a further study with more focus on action plan, 
follow-up plan and patient education, to show their association with asthma repeat ED 
visits and hospitalization.  
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Table 8 Comparison of ED relapse rates and repeat visits in 2000 versus 2001 
Number Year 2000 Year 2001 
Total episodes 330 344 
Repeat visits 63 77 
Total patients 267 267 
Relapse rates (<24 hours) 5 8 
The plan should describe the signs, symptoms, and/or peak flow values that should prompt 
increases in self-medication, contact with a health care provider, or return for emergency 
care. Patient education is a powerful tool for helping patients gain the motivation, skill, 
and confidence to control their asthma. Research shows that asthma education can be cost-
effective and can reduce morbidity, especially among high-risk patients (George, 1999). 
4.6 Conclusions 
We found that introduction of a simple treatment algorithm resulted in (1) significantly 
improved compliance with evidence based treatment but (2) no significant reductions in 
admission rates or LOS. (3) With regard to admission rate, some data suggested a lack of 
adequate assessment and decision on hospital admission partly influenced by patients’ 
choice, and this might lead to the failure to evaluate the outcome of our clinical pathway. 
In view of this, we plan a formal examination of the effect of the algorithm on EMD 
length of stay and admission rates with regards to overall cost-effectiveness. The 
questions being considered are: (a) is it worth while to keep patients 60-90 minutes longer 
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in the EMD for more intensive treatment? And (b) what is the impact of a clinical 
judgment in deciding on hospital admission? 
   35
References 
1. Aaron SD, et al. The use of ipratropium bromide for the management of acute 
asthma exacerbation in adults and children: a systematic review. J Asthma 2001; 
38:521-530. 
2. Abisheganaden J, Lim TK, et al. Peak expiratory flow rate guided protocol did 
not improve outcome in emergency room asthma. Singapore Med J 1998; 39:479-
84. 
3. Adams RJ, et al. Factors associated with hospital admissions and repeat 
emergency department visits for adults with asthma. Thorax 2000; 55:566-573. 
4. Akerman MJ, et al. A successful effort to improve asthma care outcome in an 
inner-city emergency department. J Asthma 1999 May; 36(3):295-303. 
5. Barnes PJ, et al. New aspects of asthma. J Intern Med 1992; 231:453. 
6. Barnes PJ. Cytokines as mediators of chronic asthma. Am J Respir Crit Care Med 
1994; 150:S42-49. 
7. Beveridge RC, et al. Guidelines for the emergency management of asthma in 
adults. Can Med Assoc J 1996; 155:25-37. 
8. Bloch H, et al. Intravenous magnesium sulfate as an adjunct in the treatment of 
acute asthma. Chest 1995; 107:1576-1581. 
9. Bolton MB, et al. The cost and effectiveness of an education program for adult 
who have asthma. J Gen Intern Med 1991Sep-Oct; 6(5):401-7. 
10. Brenner B, et al. The Acute Asthmatic Patient in the ED: To Admit or Discharge. 
Amer J Emerg Med 1998; 16:69-77. 
   36
11. Brenner BE. Bronchial asthma in adults: presentation to the emergency 
department. Am J Emerg Med 1983; 1: 306-333. 
12. Cairns CB, et al. Magnesium attenuates the neutrophil respiratory burst in adult 
asthmatic patients. Acad Emerg Med 1996; 3:1093-1097. 
13. Chew FT, et al. The economic cost of asthma in Singapore. Aust NZ J Med 1999; 
29: 228-233. 
14. Cockcroft DW, et al. Asthma control versus asthma severity. J Allergy Clin 
Immunol 1996; 98:1016-1018. 
15. Crim C. Clinical Practice Guidelines vs Actual Clinical Practice. Chest2000; 
118:62s-64s. 
16. Educate patients, cut return asthma visits. ED Manag. 2001 Jul; 13(7):77-8; 
suppls 1-2, 1. 
17. Emond SD, et al. 1997 National Asthma education and Prevention Program 
Guidelines: A Practical Summary for Emergency Physicians. Ann Emerg Med 
1998; 31:579-589. 
18. Evans PM, et al. Effect of inhaled corticosteroids on peripheral eosinophil counts 
and density profiles in asthma. J Allergy Clin Immunol 1993; 91:643-50. 
19. Evans R. Mullaly DI. et al. National trends in the morbidity and mortality of 
asthma in the U.S. Chest 1987; 91: Suppl 6:65S-74S. 
20. EXPERT PANEL REPORT 2. Guidelines for the Diagnosis and Management of 
Asthma. NIH Publication No. 97-4051, July 1997. 
   37
21. George MR, et al. A comprehensive educational program improves clinical 
outcome measures in inner-city patients with asthma. Arch Intern Med 1999 Aug 
9-23; 159(15):1710-6. 
22. Goldie RG, et al. Mechanisms of increased airway microvascular permeability: 
Role in airway inflammation and obstruction. Clin Exp Pharmacol Physiol 1995; 
22:387. 
23. Guidelines for Canadian Clinical Practice Guidelines, Canadian Medical 
Association, Ottawa, 1994. 
24. Horwitz RJ, et al. Inflammation and asthma. Clin chest Med 1995; 16:583. 
25. Krahn MD, Berka C, Langlois P, et al. Direct and indirect costs of asthma in 
Canada. Can Med Assoc J 1996; 154:821-831. 
26. Kuehr J, et al. Sensitization to mite allergens is a risk factor for early and late 
onset of asthma and for persistence of asthmatic signs in children. 
J Allergy Clin Immunol 1995 Mar; 95(3):655-62. 
27. Lee KH, et al. Asthma in the Elderly-A More Severe Disease. Singapore Med J 
2000; 41(12): 579-581 
28. Leung TF, et al. Inhalant allergens as risk factors for the development and 
severity of mild-to-moderate asthma in Hong Kong Chinese children. J Asthma 
2002 Jun; 39(4):323-30. 
29. Liard R, et al. Using Global Initial for Asthma guidelines to assess asthma 
severity in populations. Eur Respir J 2000; 16:615-620. 
30. McFadden ER Jr. Therapy of acute asthma. J Allergy Clin Immunol 1989; 84: 
151-8. 
   38
31. McLean RM, et al. Magnesium and its therapeutic uses: A review. Am J Med 
1994; 96:63-76. 
32. Michael F, et al. Asthma Care Practices in Chicago-Area Emergency 
Departments. CHEST 1999; 116:167S–173S. 
33. MOH Clinical Practice Guidelines-Management of Asthma 1/2002. Ministry of 
Health, Singapore. 
34. Ng TP. Adult asthma prevalence, morbidity and mortality and their relationships 
with environmental and medical care factors in Singapore. Asian Pac J Allergy 
Immunol 1999; 17:127-35. 
35. Plotnick LH, et al. Should inhaled anticholinergics be added to B2 agonists for 
treating acute childhood and adolescent asthma? A systematic review. BMJ 1998; 
317:971-977. 
36. Reid J, et al. Asthma management in the emergency department. Can Respir J 
2000; 7:255-60. 
37. Rodrigo C, et al. Assessment of the patient with acute asthma in the emergency 
department. A factor analysis study. Chest 1993; 104: 1325-8. 
38. Rodrigo G, et al. Efficacy of Magnesium Sulfate in Acute Asthma: A meta-analysis 
of randomized trials. Am J Emerg Med 2000; 18:216-221. 
39. Rowe BH, et al. Effectiveness of steroid therapy in cute exacerbations of asthma: 
a meta-analysis. Am J Emerg Med 1992; 10: 301-10. 
40. Rowe BH, et al. Intravenous Magnesium Sulfate Treatment for Acute Asthma in 
the Emergency Department: A Systematic Review of the Literature. Ann Emerg 
Med 2000; 36:181-190. 
   39
41. Rowe BH, et al. Evidence-based treatments for acute asthma. Respir Care 2001; 
46:1380-1390. 
42. Rowe BH, et al. Early emergency department treatment of acute asthma with 
systemic corticosteroids. The Cochrane Library, 1, 2002. 
43. Rowe BH, et al. Corticosteroids for preventing relapse following acute 
exacerbations of asthma. The Cochrane Library, 1, 2002. 
44. Salmeron S, et al. Asthma severity and adequacy of management in accident and 
emergency departments in France: a prospective study. The Lancet 2001; 
358:629-635. 
45. Stoodley RG, et al. The role of ipratropium bromide in the emergency 
management of acute asthma exacerbations: a meta-analysis of randomized 
clinical trials. Ann Emerg Med 1999; 34:8-18. 
46. Suh DC, et al. Impact of a targeted asthma intervention program on treatment 
costs in patients with asthma. Am J Manag Care 2001 Sep; 7(9):897-906. 
47. Tan NC. Primary Care Doctor’s Practice in the Management of Adult Asthma 
Patients. Singapore Med J 2000; 43(2):61-66. 
48. Tan NC. Relation between Morbidity and Current Treatment in Patients who 
present with Acute Asthma to Polyclinics. Singapore Med J 2000; 41(6): 259-263 
49. Thomas CC, et al. State of the art. The assessment and management of adults with 
status asthmaticus. AJRCCM 1995; 151: 1296-1316. 
50. Tiffany BR, et al. Magnesium bolus or infusion fails to improve expiratory flow in 
acute asthma exacerbations. Chest 1993; 104:831-831. 
   40
51. Vervloet D, et al. Medication requirements and house dust mite exposure in mite-
sensitive asthmatics. Allergy 1991; 46:554-8. 
52. Wallen N, et al. Glucocorticoids inhibit cytokine-mediated eosinophil survival. J 
Immunol 1991; 147:3490-5. 
53. Wan KS, et al. Evaluation of the consensus of the national asthma treatment 
guidelines in Taiwan. Acta Paediatr Taiwan 2002 May-Jun; 43(3):140-3. 
54. Weiss KB, Gergen PJ, Hodgson TA. An economic evaluation of asthma in the 
United States. N Engl J Med. 1992; 326:862-866. 
55. William W, et al. Inflammation in asthma: The cornerstone of the disease and 
target of therapy. J Allergy Clin Immunol 1998; 102:S17-S22. 
56. Woolley MJ, et al. Allergen-induced changes in bone marrow progenitors and 
airway responsiveness in dogs and the effect of inhaled budesonide on these 
parameters. Am J Respir Cell Mol Biol 1994; 11:600-6. 
 
